Innovent Biologics – Talk Bio

Actionable Insights Powered by AI

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

1 month ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, Cancer Therapeutic Procedure, co-development, global strategic partnership, IBI343, IBI363, Innovent Biologics, Neoplasms, Payments, Takeda

Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments

China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs

5 months ago talkbio0Tagged China approval, eli lilly, GCG, GCG/GLP-1 agonist, Glucagon-Like Peptide 1, Innovent Biologics, mazdutide, N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide, Obesity, Weight maintenance regimen

Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management